Neurosin Levels and Mild Cognitive Impairment
Author Information
Author(s): Menendez-Gonzalez Manuel, Castro-Santos Patricia, Calatayud Maria Teresa, Perez-Piñera Pablo, Ribacoba Renee, Martinez-Rivera Marta, Gutierrez Carmen, Lopez-Muñiz Alfonso, Suarez Ana
Primary Institution: Hospital Universitario Central de Asturias
Hypothesis
Can measuring plasmatic concentration of neurosin predict progression of mild cognitive impairment (MCI)?
Conclusion
Measuring plasmatic neurosin levels in MCI patients may help predict their conversion to dementia.
Supporting Evidence
- Neurosin levels differ significantly between MCI patients who converted to different types of dementia.
- Higher neurosin levels are associated with a higher risk of developing Dementia with vascular component.
- Repeated measurements of neurosin may help predict outcomes in MCI patients.
Takeaway
Doctors can check a substance in the blood called neurosin to see if someone with mild memory problems might get worse and develop dementia.
Methodology
Plasmatic neurosin concentrations were measured in 68 MCI patients and 70 controls, with follow-up over 18 months.
Potential Biases
Potential biases in patient selection and measurement methods.
Limitations
The study is preliminary and the sample size may limit the generalizability of the findings.
Participant Demographics
Participants were Caucasian individuals over 60 years old, including 68 MCI patients and 70 controls.
Statistical Information
P-Value
p<0.001 for developing Dementia with vascular component
Confidence Interval
95% confidence interval for risk of developing Dementia with vascular component: 11.92–14.32
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website